← Leaderboards
Nirav Thosani
University Of Texas Hlth Sci Ctr Houston
$974,403
Attributed
$1,948,805
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $676.1K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,948,805 · 1
By mechanism
R01$1,948,805 · 1
Top collaborators
- Jennifer Bailey Lundberg3 shared
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Lorraine Q. Frazier$2,996,604
- Holger K. Eltzschig$19,015,874
- Anjail Z Sharrief$3,871,852
- Yuying Liu$1,571,677
- Sunil Sheth$2,405,480
Others in their field
Other Rising Stars on “Ablation”
- Amar Nijagal · University Of California, San Francisco$3,176,680
- Rana Ramzi McKay · University Of California, San Diego$2,984,495
- Dhiraj Kumar Singh · Texas Biomedical Research Institute$2,910,982
- Francisco Altamirano · Methodist Hospital Research Institute$2,811,457
- Qin Zheng · Johns Hopkins University$2,714,830
- Robert Nathaniel Helsley · University Of Kentucky$2,651,504
Research focus
AblationAbscopal EffectAdenocarcinomaAdenosineAdoptionAnimal ModelAnti-Pd-L1Anti-Tumor Immune ResponseAntitumor ResponseBench To BedsideCancer Clinical TrialCancer DiagnosisCancer Infiltrating T CellsCancer TherapyCellsChemotherapyChemotherapy And/Or RadiationClinical CareClinically RelevantClinical TrialsClinical Trials DesignCoagulative NecrosisCollaborations5&Apos
Grant awards (3)
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer$651,173
R01 · FY2025 · CA · contact PI
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer$621,551
R01 · FY2024 · CA · contact PI
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer$676,081
R01 · FY2023 · CA